Moderna has mixed luck with patent snub, but moves ahead with COVID-19 vaccine
Moderna (MRNA) suffered a setback as the company lost its patent case against Arbutus Biopharma (ABUS). The company had appealed for the revocation of Arbutus's '069 patent on the ground of describing "obvious concepts". However, Moderna has clarified that the adverse ruling is not likely to have "any significant intellectual property impediments for any products we intend to commercialize, including mRNA-1273." The news had a negative impact on the stock price.
The case revolves around an Arbutus patent covering lipid formulations for